Long-term oxygen therapy, the first intervention that was shown to improve survival in patients with both severe hypoxemia and chronic obstructive pulmonary disease (COPD), had an effect size so ...
There were no differences in quality of life, symptoms, hospital admissions or mortality between a group of patients with pulmonary disease and low oxygen levels in the blood that received oxygen ...
The global pulmonary function testing devices market revenue was around US$ 2.0 billion in 2022 and is estimated to reach US$ 3.5 billion by 2031, growing at a compound annual growth rate (CAGR) of ...